IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanoma
I'm LongbridgeAI, I can summarize articles.IDEAYA Biosciences announced new clinical data for darovasertib in uveal melanoma at ESMO 2026. Partner Hengrui plans to present long-term Phase 1 results for IDE849 (SHR-4849) in relapsed small cell lung cancer and other NECs, targeting the start of its first registrational trial by year-end in China and other regions including the US.
- IDEAYA Biosciences flagged new clinical data disclosures at ESMO 2026 for darovasertib across metastatic and neoadjuvant uveal melanoma programs. * Partner Hengrui plans to present long-term Phase 1 results for IDE849 (SHR-4849), a DLL3 TOP1 ADC, in relapsed small cell lung cancer and other NECs. * Hengrui targets starting the first registrational trial for IDE849 by year-end in China, with initiation also planned in other regions including the US. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607170900PR_NEWS_USPR_____SF06795) on July 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)